Neuromyelitis optica: Clinical course and potential prognostic indicators

Area of Science:

• Neurology
• Immunology
• Autoimmune Diseases

Background:

• Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune neurological disorder.
• It is characterized by antibodies targeting aquaporin-4 (AQP4).
• NMOSD has been traditionally viewed as a progressive condition with accumulating disability.

Purpose of the Study:

• To evaluate the longitudinal disease course in NMOSD patients.
• To investigate the influence of AQP4 seropositivity, AQP4 serum titer levels, and plasmapheresis on NMOSD prognosis.

Main Methods:

• Retrospective chart review of 53 NMOSD patients.
• Collected data on disease course, imaging, demographics, and serum AQP4 titers.
• Calculated disability progression using EDSS scores and analyzed correlations with prognostic factors.

Main Results:

• Contrary to expectations, most patients showed no disability change (31.9%) or improvement (27.1%).
• No significant association was found between prognosis and initial AQP4 seropositivity (p=0.830).
• Initial AQP4 serum titer levels (p=0.338) and plasmapheresis (p=0.1149) also showed no significant correlation with prognosis.

Conclusions:

• This study suggests a more favorable NMOSD disease course than previously reported, potentially due to modern treatments.
• AQP4 seropositivity or titer levels may not reliably predict NMOSD prognosis.
• Further research is needed to clarify the role of plasmapheresis in NMOSD treatment.